Sunovion Pharmaceuticals Inc. Presents New Clinical Safety Data From the Pediatric Development Program for ZETONNA® (ciclesonide) Nasal Aerosol at American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting
11/12/2012 9:55:49 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that clinical study data for ZETONNA® (ciclesonide) Nasal Aerosol were presented during a scientific poster session at the annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Anaheim, California. Among the data presented were results of a safety study that evaluated the effect of ZETONNA compared with placebo on the hypothalamic pituitary adrenal (HPA) axis in pediatric patients 6 to 11 years old with perennial allergic rhinitis (PAR) (Poster #336), as well as results from a Phase III pivotal seasonal allergic rhinitis (SAR) trial that assessed the 24-hour efficacy of ZETONNA in patients 12 years of age and older (Poster #335). Additionally, one poster presented results from a scintigraphy study utilizing a radiolabelled solution of ciclesonide nasal aerosol, which provided information on nasal cavity retention as measured by radioactivity after two minutes (Poster #339).